{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,18]],"date-time":"2026-11-18T03:16:34Z","timestamp":1794971794775,"version":"4.9.1"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T00:00:00Z","timestamp":1597708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Orphanet J Rare Dis"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hypophosphatasia (HPP) is a rare, inherited metabolic disorder caused by loss-of-function mutations in the ALPL gene that encodes the tissue-nonspecific alkaline phosphatase TNAP (ORPHA 436). Its clinical presentation is highly heterogeneous with a remarkably wide-ranging severity. HPP affects patients of all ages. In children HPP-related musculoskeletal symptoms may mimic rheumatologic conditions and diagnosis is often difficult and delayed. To improve the understanding of HPP in children and in order to shorten the diagnostic time span in the future we studied the natural history of the disease in our large cohort of pediatric patients.<\/jats:p>\n                    <jats:p>This single centre retrospective chart review included longitudinal data from 50 patients with HPP diagnosed and followed at the University Children\u2019s Hospital Wuerzburg, Germany over the last 25\u2009years.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cohort comprises 4 (8%) perinatal, 17 (34%) infantile and 29 (58%) childhood onset HPP patients. Two patients were deceased at the time of data collection. Diagnosis was based on available characteristic clinical symptoms (in 88%), low alkaline phosphatase (AP) activity (in 96%), accumulating substrates of AP (in 58%) and X-ray findings (in 48%). Genetic analysis was performed in 48 patients (31 compound heterozygous, 15 heterozygous, 2 homozygous mutations per patient), allowing investigations on genotype-phenotype correlations. Based on anamnestic data, median age at first clinical symptoms was 3.5\u2009months (min. 0, max. 107), while median time to diagnosis was 13\u2009months (min. 0, max. 103). Common symptoms included: impairment of motor skills (78%), impairment of mineralization (72%), premature loss of teeth (64%), musculoskeletal pain and craniosynostosis (each 64%) and failure to thrive (62%). Up to now 20 patients started medical treatment with Asfotase alfa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Reported findings support the clinical perception of HPP being a chronic multi-systemic disease with often delayed diagnosis. Our natural history information provides detailed insights into the prevalence of different symptoms, which can help to improve and shorten diagnostics and thereby lead to an optimised medical care, especially with promising therapeutic options such as enzyme-replacement-therapy with Asfotase alfa in mind.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13023-020-01500-x","type":"journal-article","created":{"date-parts":[[2020,8,18]],"date-time":"2020-08-18T08:03:21Z","timestamp":1597737801000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":50,"title":["Pediatric hypophosphatasia: lessons learned from a retrospective single-center chart review of 50 children"],"prefix":"10.1186","volume":"15","author":[{"given":"Marius","family":"Vogt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hermann","family":"Girschick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tilmann","family":"Schweitzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Benoit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annette","family":"Holl-Wieden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Seefried","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franz","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8712-3171","authenticated-orcid":false,"given":"Christine","family":"Hofmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,8,18]]},"reference":[{"issue":"6","key":"1500_CR1","doi-asserted-by":"publisher","first-page":"822","DOI":"10.1001\/archpedi.1948.02030020840003","volume":"75","author":"JC Rathbun","year":"1948","unstructured":"Rathbun JC. Hypophosphatasia; a new developmental anomaly. Am J Dis Child. 1948;75(6):822\u201331.","journal-title":"Am J Dis Child"},{"issue":"2","key":"1500_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1172\/JCI112031","volume":"76","author":"MP Whyte","year":"1985","unstructured":"Whyte MP, Mahuren JD, Vrabel LA, Coburn SP. Markedly increased circulating pyridoxal-5\u2032-phosphate levels in hypophosphatasia. Alkaline phosphatase acts in vitamin B6 metabolism. J Clin Invest. 1985;76(2):752\u20136.","journal-title":"J Clin Invest"},{"issue":"3","key":"1500_CR3","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1007\/s00296-008-0710-9","volume":"29","author":"C Beck","year":"2009","unstructured":"Beck C, Morbach H, Richl P, Stenzel M, Girschick HJ. How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases? Rheumatol Int. 2009;29(3):229\u201338.","journal-title":"Rheumatol Int"},{"issue":"4","key":"1500_CR4","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.1172\/JCI113440","volume":"81","author":"MP Whyte","year":"1988","unstructured":"Whyte MP, Mahuren JD, Fedde KN, Cole FS, McCabe ER, Coburn SP. Perinatal hypophosphatasia: tissue levels of vitamin B6 are unremarkable despite markedly increased circulating concentrations of pyridoxal-5\u2032-phosphate. Evidence for an ectoenzyme role for tissue-nonspecific alkaline phosphatase. J Clin Invest. 1988;81(4):1234\u20139.","journal-title":"J Clin Invest"},{"issue":"5","key":"1500_CR5","doi-asserted-by":"publisher","first-page":"730","DOI":"10.1016\/0002-9343(57)90124-9","volume":"22","author":"D Fraser","year":"1957","unstructured":"Fraser D. Hypophosphatasia. Am J Med. 1957;22(5):730\u201346.","journal-title":"Am J Med"},{"issue":"3","key":"1500_CR6","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1111\/j.1469-1809.2011.00642.x","volume":"75","author":"E Mornet","year":"2011","unstructured":"Mornet E, Yvard A, Taillandier A, Fauvert D, Simon-Bouy B. A molecular-based estimation of the prevalence of hypophosphatasia in the European population. Ann Hum Genet. 2011;75(3):439\u201345.","journal-title":"Ann Hum Genet"},{"key":"1500_CR7","doi-asserted-by":"crossref","unstructured":"Hofmann C, Girschick H, Mentrup B, Graser S, Seefried S, Liese J, et al. Clinical aspects of hypophosphatasia: an update. Clin Rev Bone Miner Metab. 2013;11:60\u201370.","DOI":"10.1007\/s12018-013-9139-0"},{"issue":"Suppl 2","key":"1500_CR8","first-page":"380","volume":"10","author":"C Rockman-Greenberg","year":"2013","unstructured":"Rockman-Greenberg C. Hypophosphatasia. Pediatr Endocrinol Rev. 2013;10(Suppl 2):380\u20138.","journal-title":"Pediatr Endocrinol Rev"},{"issue":"4","key":"1500_CR9","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1038\/nrendo.2016.14","volume":"12","author":"MP Whyte","year":"2016","unstructured":"Whyte MP. Hypophosphatasia - aetiology, nosology, pathogenesis, diagnosis and treatment. Nat Rev Endocrinol. 2016;12(4):233\u201346.","journal-title":"Nat Rev Endocrinol"},{"key":"1500_CR10","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/j.bone.2015.02.022","volume":"75","author":"MP Whyte","year":"2015","unstructured":"Whyte MP, Zhang F, Wenkert D, McAlister WH, Mack KE, Benigno MC, et al. Hypophosphatasia: validation and expansion of the clinical nosology for children from 25 years experience with 173 pediatric patients. Bone. 2015;75:229\u201339.","journal-title":"Bone."},{"issue":"2","key":"1500_CR11","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.bone.2011.03.770","volume":"49","author":"MC Yadav","year":"2011","unstructured":"Yadav MC, Lemire I, Leonard P, Boileau G, Blond L, Beliveau M, et al. Dose response of bone-targeted enzyme replacement for murine hypophosphatasia. Bone. 2011;49(2):250\u20136.","journal-title":"Bone."},{"issue":"1\u20132","key":"1500_CR12","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ymgme.2017.07.010","volume":"122","author":"PS Kishnani","year":"2017","unstructured":"Kishnani PS, Rush ET, Arundel P, Bishop N, Dahir K, Fraser W, et al. Monitoring guidance for patients with hypophosphatasia treated with asfotase alfa. Mol Genet Metab. 2017;122(1\u20132):4\u201317.","journal-title":"Mol Genet Metab"},{"key":"1500_CR13","unstructured":"Strensiq [package insert] Boston MAP, Inc; January 2018."},{"key":"1500_CR14","unstructured":"Strensiq [summary of product characteristics] Ruell-Malmaison FAEM, 2018."},{"issue":"7","key":"1500_CR15","doi-asserted-by":"publisher","first-page":"2735","DOI":"10.1210\/jc.2018-02335","volume":"104","author":"CE Hofmann","year":"2019","unstructured":"Hofmann CE, Harmatz P, Vockley J, Hogler W, Nakayama H, Bishop N, et al. Efficacy and safety of Asfotase Alfa in infants and young children with Hypophosphatasia: a phase 2 open-label study. J Clin Endocrinol Metab. 2019;104(7):2735\u201347.","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"1500_CR16","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1056\/NEJMoa1106173","volume":"366","author":"MP Whyte","year":"2012","unstructured":"Whyte MP, Greenberg CR, Salman NJ, Bober MB, McAlister WH, Wenkert D, et al. Enzyme-replacement therapy in life-threatening hypophosphatasia. N Engl J Med. 2012;366(10):904\u201313.","journal-title":"N Engl J Med"},{"key":"1500_CR17","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1016\/j.jpeds.2019.01.049","volume":"209","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Leung E, Wilcox WR, Liese J, Argente J, Martos-Moreno GA, et al. Natural history of perinatal and infantile Hypophosphatasia: a retrospective study. J Pediatr. 2019;209:116\u201324 e4.","journal-title":"J Pediatr"},{"issue":"2","key":"1500_CR18","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/S2213-8587(18)30307-3","volume":"7","author":"MP Whyte","year":"2019","unstructured":"Whyte MP, Simmons JH, Moseley S, Fujita KP, Bishop N, Salman NJ, et al. Asfotase alfa for infants and young children with hypophosphatasia: 7 year outcomes of a single-arm, open-label, phase 2 extension trial. Lancet Diabetes Endocrinol. 2019;7(2):93\u2013105.","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"9","key":"1500_CR19","doi-asserted-by":"publisher","first-page":"e85971","DOI":"10.1172\/jci.insight.85971","volume":"1","author":"MP Whyte","year":"2016","unstructured":"Whyte MP, Madson KL, Phillips D, Reeves AL, McAlister WH, Yakimoski A, et al. Asfotase alfa therapy for children with hypophosphatasia. JCI Insight. 2016;1(9):e85971.","journal-title":"JCI Insight"},{"key":"1500_CR20","unstructured":"Mornet E. The tissue nonspecific alkaline phosphatase gene mutations database 2016 [updated February 7, 2016. Available from: http:\/\/www.sesep.uvsq.fr\/03_hypo_mutations.php."},{"issue":"10","key":"1500_CR21","doi-asserted-by":"publisher","first-page":"1160","DOI":"10.1038\/ejhg.2014.10","volume":"22","author":"C Hofmann","year":"2014","unstructured":"Hofmann C, Girschick H, Mornet E, Schneider D, Jakob F, Mentrup B. Unexpected high intrafamilial phenotypic variability observed in hypophosphatasia. Eur J Hum Genet. 2014;22(10):1160\u20134.","journal-title":"Eur J Hum Genet"},{"key":"1500_CR22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1186\/1471-2431-7-3","volume":"7","author":"HJ Girschick","year":"2007","unstructured":"Girschick HJ, Mornet E, Beer M, Warmuth-Metz M, Schneider P. Chronic multifocal non-bacterial osteomyelitis in hypophosphatasia mimicking malignancy. BMC Pediatr. 2007;7:3.","journal-title":"BMC Pediatr"},{"key":"1500_CR23","doi-asserted-by":"crossref","unstructured":"H\u00f6gler W,\u00a0Langman C, Gomes da Silva H, Fang S, Linglart A, Ozono K,\u00a0Petryk A, Rockman-Greenberg C,\u00a0 Seefried L,\u00a0Kishnani PS. Diagnostic delay is common among patients with hypophosphatasia: initial findings from a longitudinal, prospective, global registry. BMC Musculoskelet Disord. 2019;20:80.","DOI":"10.1186\/s12891-019-2420-8"},{"issue":"10","key":"1500_CR24","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s00296-010-1493-3","volume":"31","author":"C Beck","year":"2011","unstructured":"Beck C, Morbach H, Wirth C, Beer M, Girschick HJ. Whole-body MRI in the childhood form of hypophosphatasia. Rheumatol Int. 2011;31(10):1315\u201320.","journal-title":"Rheumatol Int"},{"key":"1500_CR25","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.bone.2016.08.019","volume":"93","author":"MP Whyte","year":"2016","unstructured":"Whyte MP, Wenkert D, Zhang F. Hypophosphatasia: natural history study of 101 affected children investigated at one research center. Bone. 2016;93:125\u201338.","journal-title":"Bone."},{"issue":"8","key":"1500_CR26","doi-asserted-by":"publisher","first-page":"1815","DOI":"10.1007\/s00198-018-4552-3","volume":"29","author":"F Genest","year":"2018","unstructured":"Genest F, Seefried L. Subtrochanteric and diaphyseal femoral fractures in hypophosphatasia-not atypical at all. Osteoporos Int. 2018;29(8):1815\u201325.","journal-title":"Osteoporos Int"},{"issue":"2","key":"1500_CR27","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s00381-008-0708-3","volume":"25","author":"H Collmann","year":"2009","unstructured":"Collmann H, Mornet E, Gattenlohner S, Beck C, Girschick H. Neurosurgical aspects of childhood hypophosphatasia. Childs Nerv Syst. 2009;25(2):217\u201323.","journal-title":"Childs Nerv Syst"},{"key":"1500_CR28","doi-asserted-by":"crossref","unstructured":"Mornet E, Hofmann C, Bloch-Zupan A, Girschick H, Le Merrer M. Clinical utility gene card for: hypophosphatasia - update 2013. Eur J Hum Genet. 2014;22(4).","DOI":"10.1038\/ejhg.2013.177"}],"container-title":["Orphanet Journal of Rare Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01500-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13023-020-01500-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13023-020-01500-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,17]],"date-time":"2021-08-17T19:51:23Z","timestamp":1629229883000},"score":1,"resource":{"primary":{"URL":"https:\/\/ojrd.biomedcentral.com\/articles\/10.1186\/s13023-020-01500-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,18]]},"references-count":28,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["1500"],"URL":"https:\/\/doi.org\/10.1186\/s13023-020-01500-x","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-23745\/v1","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-23745\/v2","asserted-by":"object"}]},"ISSN":["1750-1172"],"issn-type":[{"value":"1750-1172","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,18]]},"assertion":[{"value":"17 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The study was approved by the local.ethics committee, University of Wuerzburg, Germany.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"212"}}